Chronic Hepatitis C Infection Therapeutics
1. Olysio patent expiration
Treatment: Method of treating hepatitis c
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(3 years from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
